Skip to main content
    N

    Novavax Inc (NVAX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.06
    -0.46 (-5.45%)

    Market Cap: $1.41B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Novavax Inc (NVAX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Novavax are Vir Biotechnology (VIR), Innoviva (INVA) and Nuvation Bio (NUVB). By market cap, Novavax ranks 7th of the 13 companies on this page; Pharvaris BV (PHVS) is the largest at $2.36B.

    Peer Comparison

    NVAX's ROIC of -66.6% is below the peer median of -23.5%, and its revenue growth of -3.0% is below the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Novavax (NVAX)$1.41BN/A3.2x-18.6%-66.6%-3.0%0.00%
    Vir Biotechnology Inc (VIR)$1.71BN/A5.4x-61.0%N/A19582.0%0.00%
    Innoviva Inc (INVA)$1.35B5.3x3.0x44.1%10.8%-1.6%0.00%
    Nuvation Bio Inc (NUVB)$1.41BN/A6.7x-67.4%-18.7%242.6%0.00%
    CureVac NV (CVAC)$1.05BN/A1.8x182.1%N/A-89.0%0.00%
    Nurix Therapeutics Inc (NRIX)$1.69B6.4x2.3x42.0%N/A8426.0%0.00%
    Ultragenyx (RARE)$1.64BN/A2.2x-71.8%N/A8.1%0.00%
    Nuvectis Pharma Inc (NVCT)$696.03MN/AN/A0.0%N/A0.0%0.00%
    Maravai Lifesciences Holdings Inc (MRVI)$1.96BN/A5.2x-30.8%-28.3%10.1%0.00%
    Nektar Therapeutics (NKTR)$1.27BN/A23.9x0.0%N/A-20.4%0.00%
    Corvus Pharmaceuticals Inc (CRVS)$897.52MN/AN/A0.0%N/A0.0%0.00%
    Pharvaris BV (PHVS)$2.36BN/AN/A0.0%N/A0.0%0.00%
    Inhibrx Biosciences, Inc. (INBX)$1.23BN/A610.4x0.0%-66.0%-100.0%0.00%
    Peer median$1.38B5.8x5.2x0.0%-23.5%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Novavax, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Vir Biotechnology Inc (VIR)
    Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
    VIR competitors
    Innoviva Inc (INVA)
    Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
    INVA competitors
    Nuvation Bio Inc (NUVB)
    Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology.
    NUVB competitors
    CureVac NV (CVAC)
    CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA).
    Nurix Therapeutics Inc (NRIX)
    Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development...
    NRIX competitors
    Ultragenyx (RARE)
    Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development...
    RARE competitors
    Nuvectis Pharma Inc (NVCT)
    Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer.
    NVCT competitors
    Maravai Lifesciences Holdings Inc (MRVI)
    Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines...
    MRVI competitors
    Nektar Therapeutics (NKTR)
    Nektar Therapeutics is a biopharmaceutical company.
    NKTR competitors
    Corvus Pharmaceuticals Inc (CRVS)
    Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies.
    CRVS competitors
    Pharvaris BV (PHVS)
    Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies.
    PHVS competitors
    Inhibrx Biosciences, Inc. (INBX)
    Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates.
    INBX competitors

    Frequently Asked Questions About NVAX

    Who are Novavax's main competitors?

    The companies most similar to Novavax include Vir Biotechnology (VIR), Innoviva (INVA), Nuvation Bio (NUVB), CureVac NV (CVAC) and Nurix Therapeutics (NRIX), listed from the closest match.

    Who is Novavax's biggest competitor?

    Pharvaris BV (PHVS) is the largest of the similar companies at $2.36B; Vir Biotechnology (VIR) is the closest match by business profile, size, sector and industry.

    How does NVAX stock compare with its competitors?

    NVAX's P/S is 3.2x against a peer median of 5.2x; its net margin is -18.6% against a peer median of 0.0%.

    Which of Novavax's competitors pays a higher dividend?

    Novavax pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Novavax bigger than its competitors?

    No. Novavax is 7th by market cap among the 13 companies on this page; the largest is Pharvaris BV (PHVS) at $2.36B.